换一批Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
第一作者：
Natasha B,Leighl
第一单位：
Princess Margaret Hospital/University of Toronto, Department of Medicine, 5-222 610 University Avenue, Toronto, Ontario, Canada M5G 2M9. Natasha.Leighl@uhn.on.ca
作者：
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);癌, 小细胞(Carcinoma, Small Cell);环磷酰胺(Cyclophosphamide);无病生存(Disease-Free Survival);多柔比星(Doxorubicin);女(雌)性(Female);人类(Humans);肺肿瘤(Lung Neoplasms);男(雄)性(Male);中年人(Middle Aged);肿瘤复发, 局部(Neoplasm Recurrence, Local);挽救疗法(Salvage Therapy);存活率(Survival Rate);长春新碱(Vincristine)
DOI
10.1016/j.lungcan.2006.02.006
PMID
16597474
发布时间
2015-11-19
- 浏览4
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
